Stage 1 of the study will be conducted in toddlers enrolled at 12 through 15 months of age who previously completed a primary 3-dose infant series with a licensed pneumococcal conjugate vaccine (PCV). Stage 2 will be conducted in infants enrolled at approximately 2 months of age, who will receive the 3+1 schedule (3 infant doses followed by a toddler dose).
Age
0–1
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Stage 1:
Is previously vaccinated with 3 routine infant doses of Pneumococcal 20-valent conjugate vaccine (PCV20)
Is 12 through 15 months of age
Stage 2:
\- Is approximately 2 months of age
Both Stages:
Was born at full term (gestational age greater than or equal to 37 weeks)
You may not be if
Stage 1:
\- Has received a PCV dose at 10 months of age and older
Stage 2:
Has received prior administration of any pneumococcal vaccine
Both stages:
Has a history of invasive pneumococcal disease (IPD)
Has a known hypersensitivity to any component of V118C or PCV20 including diphtheria toxoid
Clareo Health | A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)
